Abiopharma

🔍 Congleton Jon (Director)

Company: Mineralys Therapeutics, Inc. (MLYS)

Report Date: 2026-06-30

Detailed Transactions and Holdings:

• Sold 58,000 shares of Common Stock at $25.9432 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 631,321.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 17,000 shares of Common Stock at $26.8174 per share (Direct)
  Date: 2026-06-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 614,321.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.5600 to $26.5000. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
• F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.6450 to $26.8200. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.